Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Aug;10(8):e1115-e1127.
doi: 10.1016/S2214-109X(22)00241-8.

Cervical cancer screening programmes and age-specific coverage estimates for 202 countries and territories worldwide: a review and synthetic analysis

Affiliations
Review

Cervical cancer screening programmes and age-specific coverage estimates for 202 countries and territories worldwide: a review and synthetic analysis

Laia Bruni et al. Lancet Glob Health. 2022 Aug.

Erratum in

  • Correction to Lancet Glob Health 2022; 10: e1115-27.
    [No authors listed] [No authors listed] Lancet Glob Health. 2023 Jul;11(7):e1011. doi: 10.1016/S2214-109X(23)00240-1. Epub 2023 May 15. Lancet Glob Health. 2023. PMID: 37201544 Free PMC article. No abstract available.

Abstract

Background: Cervical cancer screening coverage is a key monitoring indicator of the WHO cervical cancer elimination plan. We present global, regional, and national cervical screening coverage estimates against the backdrop of the 70% coverage target set by WHO.

Methods: In this review and synthetic analysis, we searched scientific literature, government websites, and official documentation to identify official national recommendations and coverage data for cervical cancer screening for the 194 WHO member states and eight associated countries and territories published from database inception until Oct 30, 2020, supplemented with a formal WHO country consultation from Nov 27, 2020, to Feb 12, 2021. We extracted data on the year of introduction of recommendations, the existence of individual invitation to participate, financing of screening tests, primary screening and triage tests used, recommended ages and screening intervals, use of self-sampling, and use of screen-and-treat approaches. We also collected coverage data, either administrative or survey-based, as disaggregated as possible by age and for any available screening interval. According to data completeness and representativeness, different statistical models were developed to produce national age-specific coverages by screening interval, which were transformed into single-age datapoints. Missing data were imputed. Estimates were applied to the 2019 population and aggregated by region and income level.

Findings: We identified recommendations for cervical screening in 139 (69%) of 202 countries and territories. Cytology was the primary screening test in 109 (78%) of 139 countries. 48 (35%) of 139 countries recommended primary HPV-based screening. Visual inspection with acetic acid was the most recommended test in resource-limited settings. Estimated worldwide coverage in women aged 30-49 years in 2019 was 15% in the previous year, 28% in the previous 3 years, and 32% in the previous 5 years, and 36% ever in lifetime. An estimated 1·6 billion (67%) of 2·3 billion women aged 20-70 years, including 662 million (64%) of 1·0 billion women aged 30-49 years, had never been screened for cervical cancer. 133 million (84%) of 158 million women aged 30-49 years living in high-income countries had been screened ever in lifetime, compared with 194 million (48%) of 404 million women in upper-middle-income countries, 34 million (9%) of 397 million women in lower-middle-income countries, and 8 million (11%) of 74 million in low-income countries.

Interpretation: Two in three women aged 30-49 years have never been screened for cervical cancer. Roll-out of screening is very low in low-income and middle-income countries, where the burden of disease is highest. The priority of the WHO elimination campaign should be to increase both screening coverage and treatment of detected lesions; however, expanding the efforts of surveillance systems in both coverage and quality control are major challenges to achieving the WHO elimination target.

Funding: Instituto de Salud Carlos III, European Regional Development Fund, Secretariat for Universities and Research of the Department of Business and Knowledge of the Government of Catalonia, and Horizon 2020.

Translations: For the French, Spanish translations of the abstract see Supplementary Materials section.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests The Cancer Epidemiology Research Programme (with which LB, BS, ER, and LA are affiliated) has received sponsorship for grants from Merck Sharp & Dohme and HPV test kits at no cost from Roche for research purposes. All other authors report no competing interests. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of WHO. Authors who are identified as personnel of the International Agency for Research on Cancer, WHO, are responsible alone for the views expressed in this article, and they do not necessarily represent the decisions, policy, or views of the International Agency for Research on Cancer, WHO.

Figures

Figure 1
Figure 1
Official recommended tests for primary cervical cancer screening The solid pattern indicates the recommendation of one of the tests (either cytology, HPV, or VIA). The striped pattern indicates the coexistence of more than one test, which can have the same indication or be used for different indications (eg, different tests are indicated at different ages, or in different settings or outreach). HPV=human papillomaviruses. VIA=visual inspection with acetic acid.
Figure 2
Figure 2
Ever in lifetime cervical cancer screening coverage in women aged 30–49 years in 2019 by country
Figure 3
Figure 3
Female population pyramid by cervical cancer screening status and income level in 2019 Number of women are from the 2019 UN population estimates. Countries are grouped according to the 2019 World Bank's classification.

Similar articles

Cited by

References

    1. Arbyn M, Weiderpass E, Bruni L, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020;8:e191–e203. - PMC - PubMed
    1. Vaccarella S, Lortet-Tieulent J, Saracci R, Conway DI, Straif K, Wild CP. International Agency for Research on Cancer; Lyon, France: 2019. Reducing social inequalities in cancer: evidence and priorities for research. - PubMed
    1. WHO Global strategy to accelerate the elimination of cervical cancer as a public health problem. Nov 17, 2020. https://www.who.int/publications-detail-redirect/9789240014107
    1. Ronco G, Dillner J, Elfström KM, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet. 2014;383:524–532. - PubMed
    1. Arbyn M, Ronco G, Anttila A, et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine. 2012;30(suppl 5):F88–F99. - PubMed

Publication types